which is the naturally occurring AAV serotype that is currently understood to have the best penetration of the BBB in humans. “We believe Voyager’s TRACER capsids should allow significantly ...

is the first of its kind on the market for assessing pre-existing anti-AAV antibodies. It streamlines the screening process by eliminating the need for serotype-specific assay development.